The Division of Clinical Haematology, in partnership with the UCT Clinical Research Centre, runs various clinical trials at Groote Schuur Hospital. Our collaborative efforts aim to advance treatments for various diseases and provide patients with the opportunity to access novel treatments that are in development.
The current clinical trials investigate the treatment of haematological malignancies including chronic lymphocytic leukaemia, small lymphocytic lymphoma, multiple myeloma and diffuse large B-cell lymphoma. We have previous experience with various phases of clinical trials in both benign and malignant haematological conditions.
Trials currently recruiting new patients:
MK1026-011 (BELLWAVE-011): A Study of Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
MK-2140-010 (waveLINE-010): A randomised, open-label, multicenter, phase 3 study of zilovertamab vedotin (MK-2140) in combination with R-CHP versus R-CHOP in participants with previously untreated Diffuse Large B-cell Lymphoma (DLBCL)
- CA-057-010 (Successor-1): A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM): Successor-1
Trials planning to recruit new patients in 2026:
MK1026-010 (BELLWAVE-010): A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Following at Least 1 Prior Therapy.
Please contact our sub-investigators Dr. Fiona Watt (fiona.watt@uct.ac.za), Dr. Jo Hughes (elizabeth.hughes@uct.ac.za) or Dr. Nicolé Smith (n.smith@uct.ac.za) if you would like any further information.